The future of cancer therapy: exploring the potential of patient-derived organoids in drug development

Basit Öğe Kaydı
dc.contributor.authorAvci, Cigir Biray
dc.contributor.authorBagca, Bakiye Goker
dc.contributor.authorShademan, Behrouz
dc.contributor.authorTakanlou, Leila Sabour
dc.contributor.authorTakanlou, Maryam Sabour
dc.contributor.authorNourazarian, Alireza
dc.date.accessioned2024-08-31T07:49:59Z
dc.date.available2024-08-31T07:49:59Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractCancer therapy is on the brink of a significant transformation with the inclusion of patient-derived organoids (PDOs) in drug development. These three-dimensional cell cultures, directly derived from a patient's tumor, accurately replicate the complex structure and genetic makeup of the original cancer. This makes them a promising tool for advancing oncology. In this review, we explore the practical applications of PDOs in clinical drug screening and pharmacognostic assessment, as well as their role in refining therapeutic strategies. We provide insights into the latest advancements in PDO technology and its implications for predicting treatment responses and facilitating novel drug discoveries. Additionally, we address the operational challenges associated with incorporating PDOs into the drug development process, such as scaling up organoid cultures, ensuring consistent results, and addressing the ethical use of patient-derived materials. Aimed at researchers, clinicians, and key stakeholders in oncology, this article aims to succinctly present both the extraordinary potential and the obstacles to integrating PDOs, thereby shedding light on their prospective impact on the future of cancer treatment.en_US
dc.identifier.doi10.3389/fcell.2024.1401504
dc.identifier.issn2296-634X
dc.identifier.pmid38835507en_US
dc.identifier.scopus2-s2.0-85195113235en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3389/fcell.2024.1401504
dc.identifier.urihttps://hdl.handle.net/11454/105069
dc.identifier.volume12en_US
dc.identifier.wosWOS:001236727300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers In Cell and Developmental Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectPatient-Derived Organoidsen_US
dc.subjectCancer Therapyen_US
dc.subjectDrug Developmenten_US
dc.subjectPersonalized Medicineen_US
dc.subjectPreclinical Drug Screeningen_US
dc.titleThe future of cancer therapy: exploring the potential of patient-derived organoids in drug developmenten_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu